Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease
✍ Scribed by C. Echávarri; P. Aalten; H. B. M. Uylings; H. I. L. Jacobs; P. J. Visser; E. H. B. M. Gronenschild; F. R. J. Verhey; S. Burgmans
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 274 KB
- Volume
- 215
- Category
- Article
- ISSN
- 0340-2061
No coin nor oath required. For personal study only.
✦ Synopsis
The main aim of the present study was to compare volume differences in the hippocampus and parahippocampal gyrus as biomarkers of Alzheimer’s disease (AD). Based on the previous findings, we hypothesized that there would be significant volume differences between cases of healthy aging, amnestic mild cognitive impairment (aMCI), and mild AD. Furthermore, we hypothesized that there would be larger volume differences in the parahippocampal gyrus than in the hippocampus. In addition, we investigated differences between the anterior, middle, and posterior parts of both structures. We studied three groups of participants: 18 healthy participants without memory decline, 18 patients with aMCI, and 18 patients with mild AD. 3 T T1-weighted MRI scans were acquired and gray matter volumes of the anterior, middle, and posterior parts of both the hippocampus and parahippocampal gyrus were measured using a manual tracing approach. Volumes of both the hippocampus and parahippocampal gyrus were significantly different between the groups in the following order: healthy > aMCI > AD. Volume differences between the groups were relatively larger in the parahippocampal gyrus than in the hippocampus, in particular, when we compared healthy with aMCI. No substantial differences were found between the anterior, middle, and posterior parts of both structures. Our results suggest that parahippocampal volume discriminates better than hippocampal volume between cases of healthy aging, aMCI, and mild AD, in particular, in the early phase of the disease. The present results stress the importance of parahippocampal atrophy as an early biomarker of AD.
📜 SIMILAR VOLUMES
The extent of regional atrophy in ten patients, aged 52-74 years, dying with Alzheimer's disease uncomplicated pathologically by the effects of advanced old age or cerebrovascular disease, was quantified by image analysis of fixed coronal brain slices. Atrophy of the cerebral cortex was globally dis
## Abstract Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole‐brain atrophy rates over 1 year in early and prema
With the aim of detecting mild dementias, 94 elderly subjects who had been participating in a long-term study since 1976 were studied by means of a new diagnostic instrument, the Alzheimer's Disease Assessment Scale (ADAS) (Rosen et al., 1984). Data available from intelligence tests performed during